https://www.taxtmi.com/news?id=52488 Regulatory authorization was granted for NorUDCA Tablets 500 mg as the first approved therapy targeting NAFLD, based on clinical trials showing superiority to placebo and an acceptable safety profile; the product features a dual action mechanism combining anti inflammatory effects with bile acid regulation and the manufacturer intends immediate commercialization domestically while pursuing international regulatory approvals. en-us Thu, 14 Aug 2025 12:01:05 +0530 Thu, 14 Aug 2025 12:01:05 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=52488 Regulatory authorization was granted for NorUDCA Tablets 500 mg as the first approved therapy targeting NAFLD, based on clinical trials showing superiority to placebo and an acceptable safety profile; the product features a dual action mechanism combining anti inflammatory effects with bile acid regulation and the manufacturer intends immediate commercialization domestically while pursuing international regulatory approvals. News - Thu, 14 Aug 2025 12:01:05 +0530 https://www.taxtmi.com/news?id=52488